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Changes in cancer incidence and mortality have been modest 
during the past several decades, but the number of cancer 
survivors has almost tripled during the same period. With the 
increasing cohort of cancer survivors, efforts to prevent, 
diagnose and manage adverse effects of cancer therapy, in 
general, and those of radiation therapy specifically, have 
intensified. Considerable progress towards reducing toxicity 
of radiation therapy has been achieved by the introduction of 
so-called dose-sculpting treatment techniques. Moreover, 
new insights into the underlying pathophysiology have 
resulted in an improved understanding of mechanisms of 
radiation-induced normal tissue toxicity and in development 
of new diagnostic strategies and management opportunities. 
However, the risk of normal tissue toxicity still limits the 
dose of cytotoxic therapy that can be given, thus limiting the 
curability of cancer. 
The steadily increasing number of cancer survivors and the 
demand for uncomplicated cancer cures require a paradigm 
shift in cancer survivorship research. Research must shift 
from simply describing and palliating side effects (“doing 
head-counts”) to adopt a more modern, goal-oriented 
approach. The new approach encompasses 
1) epidemiological, psychosocial, and outcomes research 
aimed at characterizing and ameliorating the problems that 
afflict current cancer survivors; 2) applied clinical and pre-
clinical research aimed at developing new treatments or 
response modifiers to prevent or minimize short- and long-
term side effects of cancer therapy; and 3) basic research 
aimed at improving our understanding of the cellular and 
molecular mechanisms that are responsible for treatment-
related toxicities. This three-pronged approach will ensure 
that progress is made toward our ultimate goal, i.e., to 
increase the uncomplicated cancer cure rate. 
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Historically, although, radiotherapy was used to palliate 
inoperable breast cancer, the principle of adjuvant 
irradiation was step by step commonly applied to improve 
local control. Thomas Hartigan (Blackfriars Hospital, London) 
used Radium radioactive sources as “contact therapy” for 
breast cancer. In 1924, Geoffrey Keynes proposed to use 
radium by interstitial implantation. By 1937, Keynes had 
performed 325 breast implants and was able to statistically 
demonstrate equivalent 5-year survival to radical 
mastectomy [1]. 
Nowadays, brachytherapy represents the smartest way to 
deliver a high dose in a small volume especially in case of 
breast cancer which is well known to be highly sensitive to 
dose escalation [2]. Currently we have to deal with new 
radiation therapy technologies from external beam to intra-
operative going through new brachytherapy devices. New 
challenges for radiation oncologists are to use the right 
radiation technique for the right patient in order to achieve 
the best clinical outcome. For brachytherapy, achieving local 
control remains a key objective but it should be obtain with a 
low rate of side effects and this concept appears strongly 
correlated with the respect of certain rules of vectors 
implantation, dose distribution constrains and target 
delineation. 
Whatever the indication, breast brachytherapy represents a 
partial irradiation of the breast. This partial breast 
irradiation (PBI) can be performed using historically 
interstitial multicatheter implants with plastic tubes or 
needles. In such situation, any type of dose rate can be used 
(low, pulsed or high) [3]. Seed implants represent another 
more recent technical approach for breast interstitial 
brachytherapy mainly used for accelerated PBI (APBI) [4]. 
Beside interstitial technique, balloon system represents 
another approach. Initially based on single catheter design 
[5], the balloon technique improved by using a multi catheter 
concept leading to better dose distribution [6]. In the future, 
electronic brachytherapy could be also used in some 
indications [7] 
While boost after whole breast post-operative irradiation has 
been the main brachytherapy indication, during the two last 
decades [8], breast brachytherapy appeared more and more 
attractive in other situations such accelerated and partial 
breast irradiation as sole therapy [9] and for second 
conservative treatment in case of ipsilateral breast tumor 
recurrence [10]. 
Last but not least, beside technological and medico-economic 
constraints, radiation oncology community has to face to 
methodological and statistic developments. In the frame of 
Evidence Based Medicine, clinical research represents the 
main asset to progress and propose validated treatments as 
brachytherapy for breast cancer. However, is it still possible 
to continue to wait 10 to 15 years after the inclusion of 
thousands of patients and the expense of thousands (millions) 
of dollars/euros? Is the “overall survival” always the smartest 
primary endpoint? What could be the next step in terms of 
clinical research for the promotion of breast brachytherapy? 
In this frame, a good example we have probably to mimic is 
represented by the EMBRACE study. This pragmatic 
international study started as a retrospective one and rapidly 
evolved as a prospective observatory data base. GEC-ESTRO 
Gynecologic group is now able to give strong clinical 
evidences to promote brachytherapy without any phase III 
randomized trials. 
Breast brachytherapy keeps going with new fractionation, 
new technical devices and probably new indications. The 
international community of radiation oncologist involved in 
breast brachytherapy has to continue to push forward with 
clinical research, teaching and reimbursement challenges. 
  
 
 
 
  
